8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Material company update
Dec 18, 2025·SEC
Neuphoria Therapeutics Inc.(NEUP)Earnings, Financials & Key Ratios
NEUP•NASDAQ
$4.57
Price updated Jun 27, 2026
AboutNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Show more
- Revenue$16M
- EBITDA-$122K+99.5%
- Net Income-$370K+98.4%
- EPS (Diluted)-0.23-130.0%
- Gross Margin100%
- EBITDA Margin-0.78%
- Operating Margin-7.21%
- Net Margin-2.36%
- ROE-1.59%+98.9%
NEUP Price & Volume
Neuphoria Therapeutics Inc. (NEUP) stock price & volume — 10-year historical chart
Loading chart...
Volatile Licensing Revenue Masks Clinical Burn Risks
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Milestone Funding Dependency
"Neuphoria Therapeutics operates as a high-risk, pre-revenue clinical entity whose financial stability is entirely contingent upon sporadic, non-recurring licensing milestones rather than sustainable commercial operations. While the company maintains a high current ratio of 14.31, this liquidity is deceptive given the consistent quarterly cash burn and the significant distortion of equity caused by $163.7 million in stock-based compensation recorded in 2025Q4. Investors should exercise extreme caution as the firm's long-term viability remains tethered to successful clinical trial outcomes and the potential for future goodwill impairment on its $8.8 million asset base."
Verdict Logic
the company's reliance on non-recurring revenue and its history of erratic cash flows, highlighted by a $3.9 million operating cash outflow in 2026Q3, suggest an unsustainable business model for long-term investors.
NEUP Growth Metrics
Neuphoria Therapeutics Inc. (NEUP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.9%
5 Years244.91%
3 Years290.11%
TTM-140.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-363.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.92%
Return on Capital
10 Years-49.56%
5 Years-65.36%
3 Years-81.03%
Last Year-3.71%
NEUP Recent Earnings
Neuphoria Therapeutics Inc. (NEUP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (44%)●Beat Revenue 3/12 qtrs (60%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.09+83.9%
$0.56
Rev
—
—
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.77-37.5%
$0.56
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$4.41-701.8%
$0.55
Rev
—
—
Q4 2025
Sep 29, 2025Metric
Actual
Est
EPS
$5.79-933.9%
$0.56
Rev
$16M-6026.1%
$264,300
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.09vs $0.56+83.9% | — |
| Q1 2026 | Feb 17, 2026 | $0.77vs $0.56-37.5% | — |
| Q4 2025 | Nov 14, 2025 | $4.41vs $0.55-701.8% | — |
| Q4 2025 | Sep 29, 2025 | $5.79vs $0.56-933.9% | $16Mvs $264,300-6026.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Neuphoria Therapeutics Inc. (NEUP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.57 | $24.73M | -19.87 | — | -2.36% | -1.59% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $216.03 | $31.89B | 24.47 | 1.39% | 13.92% | 7.55% | — | |
| $55.08 | $9.18B | 38.52 | -5.25% | 9.78% | 8.82% | — |
Compare NEUP vs Peers
Neuphoria Therapeutics Inc. (NEUP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NEUP SEC Filings & Documents
Neuphoria Therapeutics Inc. (NEUP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NEUP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NEUP Frequently Asked Questions
Neuphoria Therapeutics Inc. (NEUP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Neuphoria Therapeutics Inc.'s revenue?
Neuphoria Therapeutics Inc. (NEUP) reported $-10.5M in revenue for fiscal year 2025.
Is NEUP profitable?
Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $27.6M for fiscal year 2025.
Dividend & Returns
What is NEUP's return on equity?
Neuphoria Therapeutics Inc. (NEUP) has a return on equity (ROE) of -1.6%. Negative ROE indicates the company is unprofitable.
What is Neuphoria Therapeutics Inc.'s free cash flow?
Neuphoria Therapeutics Inc. (NEUP) generated $59.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.